Overview
A Two Week Study to Assess the Tolerability of AZD9668 in Chronic Obstructive Pulmonary Disease (COPD) Patients
Status:
Completed
Completed
Trial end date:
2008-09-01
2008-09-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of this study is to assess the tolerability (effect of drug on body) and pharmacokinetics (effect of body on drug) of AZD9668 in patients with mild to moderate COPDPhase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
AstraZeneca
Criteria
Inclusion Criteria:- Mild to moderate COPD
- Smokers or ex-smokers
- post-menopausal females
Exclusion Criteria:
- Past history or current evidence of clinically significant heart disease
- Lung disease other than COPD
- Treatment with systemic steroids within 8 weeks of study visit 2
- Treatment with antibiotics within 4 weeks of study visit 1 or study visit 2